Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Assets (2016 - 2026)

Intellia Therapeutics has reported Assets over the past 12 years, most recently at $758.8 million for Q1 2026.

  • Quarterly Assets fell 23.06% to $758.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $758.8 million through Mar 2026, down 23.06% year-over-year, with the annual reading at $842.1 million for FY2025, 29.29% down from the prior year.
  • Assets was $758.8 million for Q1 2026 at Intellia Therapeutics, down from $842.1 million in the prior quarter.
  • Over five years, Assets peaked at $1.5 billion in Q4 2022 and troughed at $758.8 million in Q1 2026.
  • The 5-year median for Assets is $1.2 billion (2024), against an average of $1.1 billion.
  • Year-over-year, Assets skyrocketed 67.78% in 2022 and then decreased 29.29% in 2025.
  • A 5-year view of Assets shows it stood at $1.5 billion in 2022, then fell by 14.42% to $1.3 billion in 2023, then dropped by 8.45% to $1.2 billion in 2024, then decreased by 29.29% to $842.1 million in 2025, then dropped by 9.9% to $758.8 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Assets are $758.8 million (Q1 2026), $842.1 million (Q4 2025), and $925.3 million (Q3 2025).